Featured Research

from universities, journals, and other organizations

Cervical Cancer Vaccine To Be Evaluated

Date:
September 24, 2007
Source:
University of Rochester Medical Center
Summary:
Four US sites have been chosen to monitor the effectiveness of the new cervical cancer vaccine. Two new HPV vaccines are currently being brought to market. Merck's vaccine -- Gardasil -- was approved federal Food and Drug Administration earlier this year and GlaxoSmithKline's Cervarix is expected to be endorsed by the agency later this year. The CDC recommends that the vaccine should be routinely given to girls at 11-12 years of age.

Two new HPV vaccines are currently being brought to market. Merck's vaccine -- Gardasil -- was approved federal Food and Drug Administration earlier this year and GlaxoSmithKline's Cervarix is expected to be endorsed by the agency later this year. The CDC recommends that the vaccine should be routinely given to girls at 11-12 years of age.
Credit: Image courtesy of University of Rochester Medical Center

Rochester has been chosen as one of four national sites to monitor the effectiveness of the new cervical cancer vaccine. The project, which is funded by the national Centers for Disease Control and Prevention (CDC), will be jointly conducted by the University of Rochester Medical Center (URMC) and the New York State Department of Health.

“Rochester has a strong history of coming together as a community to evaluate new vaccines and improve vaccination rates,” said Nancy M. Bennett, M.D., M.S., director of the URMC Center for Community Health. “This study is critical because many of the fundamental questions about a new vaccine cannot really be answered until we have been able to look at its impact on a broad population over a long period of time.”

The study is part of a CDC-led effort in cooperation with Emerging Infections Programs (EIP) based in state health departments and academic medical centers to evaluate the adoption and impact of the new human papillomaviruses (HPV) vaccine.

“Specifically, the study is an attempt to determine how many people are receiving the vaccine and whether or not it is having a measurable impact on rates of cervical cancer and its precursor lesions,” said Dale L. Morse, M.D., M.S., director of the Office of Science and Public Health, New York State Department of Health and the director of the New York State EIP.

Two new HPV vaccines are currently being brought to market. Merck’s vaccine – Gardasil – was approved federal Food and Drug Administration earlier this year and GlaxoSmithKline’s Cervarix is expected to be endorsed by the agency later this year. The CDC recommends that the vaccine should be routinely given to girls at 11-12 years of age.

In the United States, more than 15,000 people every day, or about 5.5 million people a year, get sexually transmitted HPV infections from their partners. About three out of every four sexually active people will get an HPV infection at some point during their lifetime. Most people fight off the virus and never even know they were infected. Others have warts or abnormal cell growth known as dysplasias. In the most serious cases, it progresses to cervical cancer; there are 9,700 new cases of cervical cancer in women in the United States every year. Two types of HPV, type 16 and type 18, cause about 70 percent of cervical cancers, and those are the types that the new vaccine is designed to prevent.

The Rochester team will create a consortium of Ob/Gyn physicians from the region’s three health systems and pathologists from the three laboratories that process all of the pap smears and cervical biopsies in Monroe County. The study will look at a subset of test results that indicate a more acute and invasive form of dysplasia. Researchers will combine this data with vaccination rates to see how rapidly the new vaccine is being taken up in the community and whether or not individuals diagnosed with acute dysplasia were vaccinated.

By tracking the incidence of precancerous dysplasia, rather than the cancer rates themselves, researchers will be able to more rapidly assess the impact of the vaccine. Dysplasia can take years to evolve into active cervical cancer, if at all, and the new vaccine is being administered to young women who are not yet sexually active. Even so, researchers anticipate that this effort will span several years.

The study is a homecoming of sorts for Rochester. Much of the underlying research that led to the development of the vaccine began more than 20 years ago in the labs of URMC virologists William Bonnez, M.D., Richard Reichman, M.D., and Robert Rose, Ph.D.

Rochester is also home to considerable expertise in vaccine surveillance. The University of Rochester is a member of the New York State Emerging Infections Program that is part of a 10-site national surveillance and research network of state health departments funded by the CDC. That network tracks several diseases and performs studies of the effectiveness of new vaccines after they’ve been licensed. The University is also part of a three-site network, the New Vaccine Surveillance Network, run by CDC that evaluates the impact of new vaccines and vaccine policies.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Rochester Medical Center. "Cervical Cancer Vaccine To Be Evaluated." ScienceDaily. ScienceDaily, 24 September 2007. <www.sciencedaily.com/releases/2007/09/070919144935.htm>.
University of Rochester Medical Center. (2007, September 24). Cervical Cancer Vaccine To Be Evaluated. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2007/09/070919144935.htm
University of Rochester Medical Center. "Cervical Cancer Vaccine To Be Evaluated." ScienceDaily. www.sciencedaily.com/releases/2007/09/070919144935.htm (accessed April 17, 2014).

Share This



More Health & Medicine News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com
Formerly Conjoined Twins Released From Dallas Hospital

Formerly Conjoined Twins Released From Dallas Hospital

Newsy (Apr. 16, 2014) Conjoined twins Emmett and Owen Ezell were separated by doctors in August. Now, nearly nine months later, they're being released from the hospital. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins